search
Back to results

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Primary Purpose

Neovascular Age-Related Macular Degeneration

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
REGN910-3
Intravitreal Aflibercept Injection (IAI)
Sponsored by
Regeneron Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neovascular Age-Related Macular Degeneration

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  1. Men or women ≥50 years of age with active subfoveal CNV secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye as assessed by a central reading center
  2. BCVA ETDRS letter score of 73 to 24 (Snellen equivalent of 20/40 to 20/320) in the study eye.
  3. Willing and able to comply with clinic visits and study-related procedures.
  4. Provide signed informed consent.

Key Exclusion Criteria:

  1. Evidence of CNV due to any cause other than AMD in either eye
  2. Prior IVT anti-VEGF in the study eye
  3. Evidence of DME or diabetic retinopathy (defined as more than 1 microaneurysm) in either eye in diabetic patients
  4. Any history of macular hole of stage 2 and above in the study eye

Sites / Locations

  • Regeneron Investigational Site
  • Regeneron Investigational Site 1
  • Regeneron Investigational Site 2
  • Regeneron Investigational Site 3
  • Regeneron Investigational Site 1
  • Regeneron Investigational Site 2
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site 1
  • Regeneron Investigational Site 2
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site 1
  • Regeneron Investigational Site 2
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site 1
  • Regeneron Investigational Site 2
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site 1
  • Regeneron Investigational Site 2
  • Regeneron Investigational Site
  • Regeneron Investigational Site 1
  • Regeneron Investigational Site 2
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site 1
  • Regeneron Investigational Site 2
  • Regeneron Investigational Site
  • Regeneron Investigational Site 1
  • Regeneron Investigational Site 2
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site
  • Regeneron Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

REGN910-3 (3 mg: 2 mg)

REGN910-3 (6 mg:2 mg)

Aflibercept (IAI) 2 mg

Arm Description

Participants were administered intravitreal injection of REGN910-3 (3 milligram [mg]:2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.

Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) Q8 or Q12 (beginning at Week 16 or Week 20) through Week 32.

Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI Q8 or Q12 (beginning at Week 16 or 20) or REGN910-3 (6 mg:2 mg) Q8 beginning at Week 16 through Week 32.

Outcomes

Primary Outcome Measures

Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Best Corrected Visual Acuity (BCVA) score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.
Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 36.

Secondary Outcome Measures

Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12
Central Sub-field Retinal Thickness (CST) was assessed using Spectral Domain Optical Coherence Tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from last observation carried forward (LOCF) post-baseline value at Week 12.
Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36
CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 36.
Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12
Choroidal neovascularization (CNV) was evaluated using fluorescein angiography (FA).CNV area values measured in square millimeters (mm^2); lower values represent better outcomes.
Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 36
Choroidal neovascularization (CNV) was evaluated using fluorescein angiography (FA).CNV area values measured in square millimeters (mm^2); lower values represent better outcomes.
Change From Baseline in Total Lesion Area at Week 12
Total lesion area was evaluated using fluorescein angiography (FA). Lesion area values measured in square millimeters (mm^2); lower values represent better outcomes.
Change From Baseline in Total Lesion Area at Week 36
Total lesion area was evaluated using fluorescein angiography (FA). Lesion area values measured in square millimeters (mm^2); lower values represent better outcomes.

Full Information

First Posted
March 14, 2016
Last Updated
May 1, 2019
Sponsor
Regeneron Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT02713204
Brief Title
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
Acronym
ONYX
Official Title
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
March 31, 2016 (Actual)
Primary Completion Date
October 3, 2017 (Actual)
Study Completion Date
October 3, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Regeneron Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neovascular Age-Related Macular Degeneration

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
365 (Actual)

8. Arms, Groups, and Interventions

Arm Title
REGN910-3 (3 mg: 2 mg)
Arm Type
Experimental
Arm Description
Participants were administered intravitreal injection of REGN910-3 (3 milligram [mg]:2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
Arm Title
REGN910-3 (6 mg:2 mg)
Arm Type
Experimental
Arm Description
Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) Q8 or Q12 (beginning at Week 16 or Week 20) through Week 32.
Arm Title
Aflibercept (IAI) 2 mg
Arm Type
Experimental
Arm Description
Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI Q8 or Q12 (beginning at Week 16 or 20) or REGN910-3 (6 mg:2 mg) Q8 beginning at Week 16 through Week 32.
Intervention Type
Drug
Intervention Name(s)
REGN910-3
Intervention Type
Drug
Intervention Name(s)
Intravitreal Aflibercept Injection (IAI)
Other Intervention Name(s)
EYLEA® (aflibercept) Injection, BAY86-5321
Primary Outcome Measure Information:
Title
Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12
Description
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Best Corrected Visual Acuity (BCVA) score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.
Time Frame
At Week 12
Title
Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36
Description
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 36.
Time Frame
At Week 36
Secondary Outcome Measure Information:
Title
Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12
Description
Central Sub-field Retinal Thickness (CST) was assessed using Spectral Domain Optical Coherence Tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from last observation carried forward (LOCF) post-baseline value at Week 12.
Time Frame
At Week 12
Title
Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36
Description
CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 36.
Time Frame
At Week 36
Title
Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12
Description
Choroidal neovascularization (CNV) was evaluated using fluorescein angiography (FA).CNV area values measured in square millimeters (mm^2); lower values represent better outcomes.
Time Frame
At Week 12
Title
Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 36
Description
Choroidal neovascularization (CNV) was evaluated using fluorescein angiography (FA).CNV area values measured in square millimeters (mm^2); lower values represent better outcomes.
Time Frame
At Week 36
Title
Change From Baseline in Total Lesion Area at Week 12
Description
Total lesion area was evaluated using fluorescein angiography (FA). Lesion area values measured in square millimeters (mm^2); lower values represent better outcomes.
Time Frame
At Week 12
Title
Change From Baseline in Total Lesion Area at Week 36
Description
Total lesion area was evaluated using fluorescein angiography (FA). Lesion area values measured in square millimeters (mm^2); lower values represent better outcomes.
Time Frame
At Week 36
Other Pre-specified Outcome Measures:
Title
Proportion of Participants With No Retinal and/or Subretinal Fluid at Week 12
Description
Retinal and/or subretinal fluid was assessed using intraretinal fluid (IRF) cystoid edema and subretinal fluid (SRF) in the center subfield on optical coherence tomography (OCT). If answers were "no" to both measurements, there was no retinal and/or subretinal fluid (Dry); if "yes" to any of the 2 measurements, there was retinal and/or subretinal fluid (Not Dry); other than the previous 2 cases, retinal and/or subretinal fluid was undetermined.
Time Frame
At Week 12
Title
Proportion of Participants With No Retinal and/or Subretinal Fluid From Baseline Through Week 36
Description
Retinal and/or subretinal fluid was assessed using intraretinal fluid (IRF) cystoid edema and subretinal fluid (SRF) in the center subfield on OCT. If answers were "no" to both measurements, there was no retinal and/or subretinal fluid (Dry); if "yes" to any of the 2 measurements, there was retinal and/or subretinal fluid (Not Dry); other than the previous 2 cases, retinal and/or subretinal fluid was undetermined.
Time Frame
Baseline through Week 36
Title
Time to No Retinal and/or Subretinal Fluid Through Week 36
Description
Kaplan-Meier estimated time to no retinal and/or subretinal fluid through week 36 (days). Retinal and/or subretinal fluid was assessed using intraretinal fluid (IRF) cystoid edema and subretinal fluid (SRF). If answers were "no" to both measurements, there was no retinal and/or subretinal fluid (Dry); if "yes" to any of the 2 measurements, there was retinal and/or subretinal fluid (Not Dry); other than the previous 2 cases, retinal and/or subretinal fluid was undetermined.
Time Frame
Baseline through Week 36

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Men or women ≥50 years of age with active subfoveal CNV secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye as assessed by a central reading center BCVA ETDRS letter score of 73 to 24 (Snellen equivalent of 20/40 to 20/320) in the study eye. Willing and able to comply with clinic visits and study-related procedures. Provide signed informed consent. Key Exclusion Criteria: Evidence of CNV due to any cause other than AMD in either eye Prior IVT anti-VEGF in the study eye Evidence of DME or diabetic retinopathy (defined as more than 1 microaneurysm) in either eye in diabetic patients Any history of macular hole of stage 2 and above in the study eye
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trial Management
Organizational Affiliation
Regeneron Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Regeneron Investigational Site
City
Mobile
State/Province
Alabama
Country
United States
Facility Name
Regeneron Investigational Site 1
City
Phoenix
State/Province
Arizona
Country
United States
Facility Name
Regeneron Investigational Site 2
City
Phoenix
State/Province
Arizona
Country
United States
Facility Name
Regeneron Investigational Site 3
City
Phoenix
State/Province
Arizona
Country
United States
Facility Name
Regeneron Investigational Site 1
City
Tucson
State/Province
Arizona
Country
United States
Facility Name
Regeneron Investigational Site 2
City
Tucson
State/Province
Arizona
Country
United States
Facility Name
Regeneron Investigational Site
City
Arcadia
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
Bakersfield
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
Beverly Hills
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
Encino
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site 1
City
Los Angeles
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site 2
City
Los Angeles
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
Mountain View
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
Oceanside
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site 1
City
Palm Desert
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site 2
City
Palm Desert
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
Palo Alto
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
Poway
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
Redlands
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
Sacramento
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
Santa Maria
State/Province
California
Country
United States
Facility Name
Regeneron Investigational Site
City
New London
State/Province
Connecticut
Country
United States
Facility Name
Regeneron Investigational Site
City
Altamonte Springs
State/Province
Florida
Country
United States
Facility Name
Regeneron Investigational Site
City
Fort Lauderdale
State/Province
Florida
Country
United States
Facility Name
Regeneron Investigational Site
City
Lakeland
State/Province
Florida
Country
United States
Facility Name
Regeneron Investigational Site
City
Largo
State/Province
Florida
Country
United States
Facility Name
Regeneron Investigational Site
City
Miami
State/Province
Florida
Country
United States
Facility Name
Regeneron Investigational Site
City
Naples
State/Province
Florida
Country
United States
Facility Name
Regeneron Investigational Site
City
Palm Beach
State/Province
Florida
Country
United States
Facility Name
Regeneron Investigational Site
City
Tallahassee
State/Province
Florida
Country
United States
Facility Name
Regeneron Investigational Site
City
Winter Haven
State/Province
Florida
Country
United States
Facility Name
Regeneron Investigational Site
City
Augusta
State/Province
Georgia
Country
United States
Facility Name
Regeneron Investigational Site
City
Decatur
State/Province
Georgia
Country
United States
Facility Name
Regeneron Investigational Site
City
'Aiea
State/Province
Hawaii
Country
United States
Facility Name
Regeneron Investigational Site 1
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
Regeneron Investigational Site 2
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
Regeneron Investigational Site
City
Lemont
State/Province
Illinois
Country
United States
Facility Name
Regeneron Investigational Site
City
Oak Forest
State/Province
Illinois
Country
United States
Facility Name
Regeneron Investigational Site
City
Oak Park
State/Province
Illinois
Country
United States
Facility Name
Regeneron Investigational Site
City
Urbana
State/Province
Illinois
Country
United States
Facility Name
Regeneron Investigational Site
City
New Albany
State/Province
Indiana
Country
United States
Facility Name
Regeneron Investigational Site
City
Des Moines
State/Province
Iowa
Country
United States
Facility Name
Regeneron Investigational Site
City
Metairie
State/Province
Louisiana
Country
United States
Facility Name
Regeneron Investigational Site 1
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
Regeneron Investigational Site 2
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
Regeneron Investigational Site
City
Chevy Chase
State/Province
Maryland
Country
United States
Facility Name
Regeneron Investigational Site 1
City
Boston
State/Province
Massachusetts
Country
United States
Facility Name
Regeneron Investigational Site 2
City
Boston
State/Province
Massachusetts
Country
United States
Facility Name
Regeneron Investigational Site
City
Jackson
State/Province
Michigan
Country
United States
Facility Name
Regeneron Investigational Site
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
Regeneron Investigational Site
City
Saint Louis
State/Province
Missouri
Country
United States
Facility Name
Regeneron Investigational Site
City
Las Vegas
State/Province
Nevada
Country
United States
Facility Name
Regeneron Investigational Site
City
Portsmouth
State/Province
New Hampshire
Country
United States
Facility Name
Regeneron Investigational Site
City
Edison
State/Province
New Jersey
Country
United States
Facility Name
Regeneron Investigational Site
City
Teaneck
State/Province
New Jersey
Country
United States
Facility Name
Regeneron Investigational Site
City
Albuquerque
State/Province
New Mexico
Country
United States
Facility Name
Regeneron Investigational Site
City
Albany
State/Province
New York
Country
United States
Facility Name
Regeneron Investigational Site
City
Bloomfield
State/Province
New York
Country
United States
Facility Name
Regeneron Investigational Site
City
Great Neck
State/Province
New York
Country
United States
Facility Name
Regeneron Investigational Site
City
Hauppauge
State/Province
New York
Country
United States
Facility Name
Regeneron Investigational Site
City
Rochester
State/Province
New York
Country
United States
Facility Name
Regeneron Investigational Site
City
Syracuse
State/Province
New York
Country
United States
Facility Name
Regeneron Investigational Site
City
Asheville
State/Province
North Carolina
Country
United States
Facility Name
Regeneron Investigational Site
City
Charlotte
State/Province
North Carolina
Country
United States
Facility Name
Regeneron Investigational Site
City
Durham
State/Province
North Carolina
Country
United States
Facility Name
Regeneron Investigational Site
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
Regeneron Investigational Site
City
Dublin
State/Province
Ohio
Country
United States
Facility Name
Regeneron Investigational Site
City
Portland
State/Province
Oregon
Country
United States
Facility Name
Regeneron Investigational Site
City
Camp Hill
State/Province
Pennsylvania
Country
United States
Facility Name
Regeneron Investigational Site
City
Huntingdon
State/Province
Pennsylvania
Country
United States
Facility Name
Regeneron Investigational Site
City
Ladson
State/Province
South Carolina
Country
United States
Facility Name
Regeneron Investigational Site
City
Rapid City
State/Province
South Dakota
Country
United States
Facility Name
Regeneron Investigational Site
City
Germantown
State/Province
Tennessee
Country
United States
Facility Name
Regeneron Investigational Site
City
Knoxville
State/Province
Tennessee
Country
United States
Facility Name
Regeneron Investigational Site
City
Nashville
State/Province
Tennessee
Country
United States
Facility Name
Regeneron Investigational Site
City
Abilene
State/Province
Texas
Country
United States
Facility Name
Regeneron Investigational Site 1
City
Austin
State/Province
Texas
Country
United States
Facility Name
Regeneron Investigational Site 2
City
Austin
State/Province
Texas
Country
United States
Facility Name
Regeneron Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
Regeneron Investigational Site 1
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
Regeneron Investigational Site 2
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
Regeneron Investigational Site
City
Harlingen
State/Province
Texas
Country
United States
Facility Name
Regeneron Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
Regeneron Investigational Site
City
The Woodlands
State/Province
Texas
Country
United States
Facility Name
Regeneron Investigational Site
City
Willow Park
State/Province
Texas
Country
United States
Facility Name
Regeneron Investigational Site
City
Salt Lake City
State/Province
Utah
Country
United States
Facility Name
Regeneron Investigational Site
City
Madison
State/Province
Wisconsin
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

We'll reach out to this number within 24 hrs